GB2043070A - Preparation of sodium cefuroxime - Google Patents

Preparation of sodium cefuroxime Download PDF

Info

Publication number
GB2043070A
GB2043070A GB8005088A GB8005088A GB2043070A GB 2043070 A GB2043070 A GB 2043070A GB 8005088 A GB8005088 A GB 8005088A GB 8005088 A GB8005088 A GB 8005088A GB 2043070 A GB2043070 A GB 2043070A
Authority
GB
United Kingdom
Prior art keywords
sodium
cefuroxime
mixture
added
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB8005088A
Other versions
GB2043070B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of GB2043070A publication Critical patent/GB2043070A/en
Application granted granted Critical
Publication of GB2043070B publication Critical patent/GB2043070B/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/247-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/26Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
    • C07D501/34Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group with the 7-amino radical acylated by carboxylic acids containing hetero rings

Description

1 GB 2 043 070A 1
SPECIFICATION
Improvements in or relating to the preparation of sodium cefuroxime This invention relates to a new process for the preparation of the sodium salt of the cephalosporin antibiotic (6R,7R)-3-carbamoyloxymethyi-7-[Z-2(fur-2-yi)-2-methoxyiminoacetamido]ceph-3-em-4-carboxylic acid, which has the approved name---cefuroxime---.
Cefuroxime, as described and claimed in British Patent Specification No. 1,453,049 is a valuable broad spectrum antibiotic characterised by high activity against a wide range of grampositive and gram-negative microorganisms, this property being enhanced by the very high stability of the compound to fl-lactarnases produced by a range of gram-negative microorganisms. Additionally the compound is stable in the body owing to its resistance to the action of mammalian esterases, and gives high serum levels following parenteral administration to human and animal subjects, while exhibiting low serum binding.
Cefuroime may be administered, in human or veterinary medicine, as a nontoxic derivative, 15 i.e. one which is physiologically acceptable in the dosage at which it is administered. Such non toxic derivatives conveniently include those salts, e.g. alkali metal, alkaline earth metal and organic base salts which on admixture with sterile, pyrogen-free water form aqueous solutions or suspensions for injection. In British Patent Specification No. 1,453,049 the sodium salt of cefuroxime is described as being a substance well suited to administration on injection. For 20 convenience this sodium salt will hereinafter be referred to as sodium cefuroxime.
One process described in British Patent Specification No. 1,453,049 for the preparation of the parent antibiotic, cefuroxime, involves the carbamoylation of an appropriate 3-hydroxymethyl compound with inter alia an isocyanate of formula RNCO (wherein R is a labile substituent) and subsequent cleavage of the N-protected ca rba moyloxym ethyl group at the 3-position to form the 25 desired 3-carbamoyloxymethyl compound. The parent acid may then be treated with for example sodium 2-ethylhexanoate to form sodium cefuroxime. Cleavage of the above- mentioned N protected group may be effected for example by aqueous hydrolysis in the presence of methanol and sodium bicarbonate.
There are disadvantages in carrying out the above cleavage in an aqueous medium. The 30 carbamoylation of the appropriate 3-hydroxymethyl compound is preferably effected in non hydroxylic solvents and hence an extraction is necessary to transfer the product to an aqueous medium. Unless the extract is subjected to further treatment, this extraction will not generally provide an aqueous slution at a suitable concentration for direct isolation of the cefuroxime as the sodium salt, particularly in view of the solubility of the salt in water.
We have now discovered that the 3-N-protected carbamoyloxymethyl group can be cleaved in such a manner that sodium cefuroxime can be obtained directly without the need to isolate the parent acid. The resulting sodium cefuroxime can thus be obtained in good yield and with good purity and crystallinity. Moreover, the resulting sodium cefuroxime can be readily recrystallised under sterile conditions.
According to a preferred feature of the present invention we provide a process for the preparation of sodium cefuroxime, if desired as a solvate, which comprises subjecting a compound of formula H H 45 S C. CO. NH 0 9. -;L OCONHR N 0 50 OCH 3 0 COOH (wherein R' is a base-labile group) to alcoholysis in a substantially anhydrous solvent medium in the presence of a basic catalyst soluble in the said medium which basic catalyst comprises the 55 sodium salt of a acid having a pK. value not less than 3.5, and subsequently recovering sodium cefuroxime or a solvate thereof. Examples of base-labile groups R, which may be readily cleaved in the above-described process include chlorinated lower (e.g. C,J alkanoyl groups such as di or trichloroacetyl.
The sodium salt employed as basic catalyst in the above process may be selected from the 60 sodium salts of acids having pK,, values not less than 3.5 provided that the salt has sufficient solubility in the anhydrous solvent medium to impart the desired catalytic effect. The salt is preferably a salt of a carboxylic acid, particularly a C,_,o alkanoic acid, examples of such salts including sodium acetate, sodium propionate and sodium 2-ethy[hexanoate, the latter being especially preferred. The base may be added to the reaction medium as a solid or as a solution 65 2 GB 2 043 070A 2 in an alcohol, for example, the alcohol which is used to effect the above- mentioned alcoholysis reaction.
The alcoholysis reaction is advantageously effected using a lower (C,-,) alkanol such as methanol, ethanol or isopropanol, methanol being particularly preferred; a glycol, for example a lower (C2-,) alkane glycol such as ethane-1,2-diol or propane- 1, 2-diol, ethane-1,2-diol being particularly preferred, or a glycol having recurring units of 2 to 4 carbon atoms such as diethylene glycol; or a mixture of a lower alkanol and a glycol, methanol and/or ethane-1,2-diol being particulary preferred as a component of such a mixture.
The anhydrous solvent medium generally comprises one or more inert organic solvents, for example, aromatic solvents such as toluene; aliphatic hydrocarbons such as hexane; chlorinated hydrocarbons such as dichloromethane; esters such as ethyl acetate and butyl acetate; ketones such as aceto6e and methyl ethyl ketone; ethers such as tetrahydrofuran and dioxan; and nitriles such as acetonitrile.
The solvent medium is preferably selected to provide a medium in which the sodium salt of the above compound of formula (1) is substantially soluble and from which sodium cefuroxime 15 can be readily crystallised.
A preferred solvent medium for the above alcoholysis reaction is tetrahydrofuran or a mixture thereof with dichloromethane or hexane since such solvent systems provide sodium cefuroxime in particularly good crystalline form, for example, with regard to colour and ease of characterisa- tion. A further advantage in using solvent systems comprising tetrahydrofuran is that the resulting sodium cefuroxime is generally formed as the tetrahydrofuran solvate in a high degree of purity. A substantial proportion of the tetrahydrofuran in such a solvate may then be displaced during any filtration and/or drying procedures of the salt by, for example, washing the filtered solvate with ethanol or drying the solvate in a stream of moist air.
The alcoholysis reaction is preferably effected at an initial pH in the range 6.0 to 8.0, 26 particularly about 7.0, although during the reaction the pH may rise to about 10. The reaction is conveniently carried out at a temperture in the range of 5' to 60C, preferably at 15 to 30C, a temperature of about 25'C being particularly preferred.
The above-mentioned substantially anhydrous solvent medium preferably contains less than 1 %, particularly less than 0. 2%, of water.
After completion of the alcoholysis reaction, the precipitated sodium cefuroxime can be separated from the solvent medium for example by filtration and, if desired, washed with an anhydrous solvent of the type described above.
The above-identified starting material of formula (1) may be prepared for example by reaction of a corresponding 3-hydroxymethyl compound with an appropriate isocyanate of formula 35 R'NCO (wherein R1 is as defined above), e.g. as described in British Patent Specification No.
1,453,049.
The following Examples serve to illustrate the invention. All temperatures are in C.
Tetrahydrofuran is represented as THF and gas-liquid chromatography is represented as G.L.C.
Hyflo Supercel is a siliceous filter aid.
Example 1
Sodium cefuroxime THF solvate To a flask, protected from moisture by a silica gel tube, was added THF (60 mi), dichloromethane (25 mi) and trichloroacetyl isocyanate (6.2 m[). The solution was cooled to 45 - 10'. With efficient stirring (6R,7R)-[Z-2-(fur-2-yl)-2methoxyiminoacetamido]ceph-3-em-4-car- boxylic acid (10. 0 9) was added in one charge followed by TH F (20 m]). The temperature of the slurry rose rapidly and the cooling was manipulated to give a final temperature of 5. A slightly opaque solution had been produced after about 30 seconds. This was stirred at 5' for 10 minutes. Cooling was then discontinued and methanol (25 m[) added in one charge. The solution temperature rose almost instantaneously at 1 T. After a further 5 minutes stirring the solution was filtered. Once dry the filtler bed was washed with THF (10 mi) and sucked dry.
The solution was warmed to 22' and sodium 2-ethylhexanoate (17.5 g) added in one charge.
All the solid had dispersed after 5 minutes stirring leaving a slightly cloudy solution. The temperature rose to 25'. The slurry was filtered after crystallisation for 2 hours without cooling. 55 The filter cake was washed by displacement with 1: 1 TI- IF:dichloromethane (2 X 50 mi) and dried. The product was dried overnight at 35' in vacuo to yield sodium cefuroxime THF solvate (12.41 g).
lk [a]20 + 54.6'. E1%,343.
D 1 1 c The isolated product was shown by G.L.C. to contain 12.4% w/w of THF Example 2 6 5 Sodium cefuroxime THF solvate 1 t, 3 GB 2 043 070A 3 To a flask protected from moisture by a silica gel tube was added THF (70 m]), dichforomethane (25 mi) and trichloroacetyl isocyanate (6.2 mi). The solution was cooled to - 10. With efficient stirring (6R,7R)-[Z-2-(fur-2yi)-2-methoxyiminoacetamido]-3-hydroxymethylceph-3-em-4carboxylic acid (10 9) was added in one charge followed by TH F (20 mi). The temperature of the mixture was allowed to rise to 5'. The slightly opaque solution was stirred at 5' for 10 minutes. Cooling was discontinued and methanol (2.5 mi) added. After a further minute a previously prepared solution of sodium 2-ethylhexanoate (12.5 g) in methanol (20 mi) was added in one charge. With stirring, the temperature of the solution was raised to 25' over 2-3 minutes. The stirrer was then stopped and the batch left for 1 hour at 25'. Crystallisation commenced about 10 minutes after the additon of the base. After 1 hour the thick slurry was 10 stirred for 1 minute before leaving it a further hour unstirred at 25'.
The batch was filtered and the filter cake washed with 1: 1 THF:dichloromethane (2 X 50 mi). The wet cake was dried at 35' in vacuo to produce sodium cefuroxime THF solvate (12.25 g).
[a] 20 + 53.8 E%343.
D 1 1 c The isolated product was shown by G.L.C. to contain 10.7% w/w of THF.
Example 3 20 Sodium cefuroxime A mixture of THF (130 mi), dichloromethane (45 mi), and trichloroacetyl isocyanate (9.3 mi) was protected from moisture and cooled to - 10'. To the stirred mixture was added (6R,7R)-7[Z-2-(fur-2-yi)-2methoxyiminoacetamido]-3-hydroxymethylceph-3-em-4 -carboxylic acid (20 g) in one charge followed by TH F (40 mi). The mixture was stirred for 10 minutes at 0' to + 5' and then warmed to 22. There was then added, in one charge, a solution of sodium 2- ethylhexanoate (20 g) in methanol (40 m[) and, after stirring for 1 minute, the mixture was left undisturbed at 25' for 2 hours to crystallise. The crystalline material was collected by filtration, washed with ethanol (2 X 100 mi), and dried in vacuo at 35' to give sodium cefuroxime (24.1 g). The isolated product was shown by G.L.C. to contain 5.3% w/w of ethanol, 0.6% w/w of THF, and 0.04% w/w of methanol.
Example 4
Sodium cefuroxime A mixture of THF (60 mi), dichforomethane (25 mi), and trichloroacetyl isocyanate (6.2 mi) was protected from moisture and cooled to - 10'. To the stirred mixture was added (6R,7R)-[Z2-(fur-2-yl)-2-methoxyiminoacetamido]-3-hydroxymethylceph-3-em-4carboxylic acid (10 g) in one charge followed by THF (20 m]). The mixture was stirred for 10 minutes at 0' to + 5, to give a clear solution. Methanol (6.6 mi) was added, followed by portionwise addition of anhydrous sodium acetate (0.3 9) to raise the pH to 3.5. Charcoal (1 g) and filtler aid (0.5 g Hyfio Supercel) were added and the mixture stirred at 10' for 20 minutes. Further anhydrous 40 sodium acetate (5 g) was then added and the mixture stirred at 10' to 15' for 5 minutes by which time the pH had risen to 7.2. The charcoal, undissolved sodium acetate, and filter aid were removed by filtration and the filter bed washed with methanol (23 mi) containing dichloromethane (10 mi). The filtrate and washes were combined, warmed to 25, and left undisturbed at that temperature. Crystallisation commenced after 12 minutes. After 1 hour the 45 mixture was stirred briefly and then left undisturbed for a further 1 -,- hours. The crystalline material was collected by filtration, washed with THF (2 X 50 mi) and dried in vacuo at 35, to give sodium cefuroxime in a yield of 78.5% theory corrected for THF and sodium acetate.
Example 5
Sodium cefuroxime THFsolvate A mixture of THF (60 mi), dichloromethane (25 mi), and trichforoacetyl isocyanate (6.2 mi) was protected from moisture and cooled to - 10'. to the stirred mixture was added (6R,7R)-7 [Z-2-(fur-2-yi)-2-methoxyiminoacetamidol-3-hydroxymethylceph-3-em-4carboxyl ic acid (10 g) in one charge followed by THF (20 m]). The temperature was controlled in the range 0' to + 5 and the mixture stirred for 10 minutes. Ethane-1,2-diol (15 mi) was added followed by a solution of sodium 2-ethylhexanoate (10 g) in THF (20 mi) to raise the pH to 7.3. The mixture was warmed to 25' and left indisturbed for 1 hour. The mixture was then stirred briefly and left undisturbed for a further hour. The crystalline material which had separated from the mixture was collected by filtiration, washed with THF (2 X 50 mi), and dried in vacuo at 35 to yield 60 sodium cefuroxime (10. 76 g) TH F solvate. The isolated product was shown by G. L.C. to contain 8.8% w/w of THF and 0.56% w/w of ethane1, 2-diol.
Example 6
Sodium cefuroxime 4 GB 2 043 070A 4 The reaction and crystallisation were performed as in Example 5. The crystalline material was collected by filtration, washed with ethanol (2 X 50 mi), and dried in vacuos at ambient temperature to yield sodium cefuroxime (10 g). The isolated product was shown by G.L.C. to contain 5. 6% w/w of ethanol, less than 0.07% w/w of THIF, and 0,47% w/w of ethane1, 2diol.
Example 7 Sodium cefuroxime (6R,7R)-[Z-2-(fur-2-yi)-2methoxyiminoacetamido]-3-hydroxymethylceph-3-em-4-c arboxylic acid (1.0 g) was stirred with acetone (20 m]) and the mixture cooled to 0. To this mixture was 10 added trichloroacetyl isocyanate (0.63 mi) and the temperature maintained in the range 0' to 5 with efficient stirring. After 20 minutes there was added ethanol (1 mi) followed by a solution of sodium 2-ethylhexanoate (1. 2 g) in acetone (4 m]) to adjust the mixture to pH 6.5. The mixture was stirred for 21/, hours without cooling and then filtered. The solid so obtained was washed with acetone and dried in vacuo at 35' to give sodium cefuroxime (0.9 g).
Example 8
Sodium cefuroxime To a mixture of 1,2-dichloroethane (140 mi) and acetone (10 mi) was added trichloroacetyl isocyanate (6.25 mi) followed by (6R,7R)-3-[Z-2-(fur-2-yi)-2- methoxyiminoacetamido]-3-hydroxymethylceph-3-em-4-carboxylic acid (10.0 g) with stirring and cooling to keep the temperature in the range 0' to 5. The mixture was stirred for 15 minutes and acetone (10 mi) was added.
After stirring for a further 30 minutes there was added methanol (10 mi) followed by solid sodium 2-ethy[hexanoate (6.2 g) to bring the mixture to pH 7. The temperature was adjusted to 25 and the mixture stirred for 41 hours. The crystalline solid which separated from the mixture 25' was collected by filtration, washed with one bed volume of 1,2- dichlorethane followed by two bed volumes of acetone, and dried in vacuo at 35' to give sodium cefuroxime (10.24 g).
Example 9
Sodium cefuroxime To ethyl acetate (125 mi) was added trichloroacetyl isocyanate (6.25 mi) followed by (6R,7R)[Z-2-(fur-2-yi)-2-methoxyiminoacetamido]-3hydroxymethylceph-3-em-4-c arboxylic acid (10.0 g) with stirring and cooling to keep the temperature in the range 0' to 5. A line wash of ethyl acetate (25 mi) was added and the mixture stirred for 30 minutes. Methanol (10 m]) and charcoal (1 g) were added and the mixture stirred for 5 minutes before filtration through a bed of Hyflo Supercel. The bed was washed with ethyl acetate (2 X 20 mi) and the colourless filtrate and washes combined. To the bulked ethyl acetate liquors was added sodium 2-ethyihexanoate (12 g) in ethyl acetate (40 mi) until the pH was 7. 1. The mixture was warmed to 25 and maintained at 25' for 4-21- hours with stirring. The crystalline material which separated from the mixture was collected by filtration, washed with ethyl acetate followed by acetone, and dried in 40 vacuo at 35' to give sodium cefuroxime (11.49 g).
Example 10
Sodium cefuroxime To 1,2-dimethoxyethane (125 mi) was added trichloroacetyl isocyanate (6. 25 m]) followed by 45 (6R,7R)-[Z-2-(fur-2-yi)-2-methoxyiminoacetamido]-3-hydroxymethylceph-3-em4-c arboxylic acid(l 0.0 g) with stirring and cooling to keep the temperature in the range 0' to W. A line wash of 1,2-dimethoxyethane (25 m]) was added and the mixture stirred for 20 minutes. Trichloroace tyl isocyanate (3.1 mi) was added and the mixture stirred for a further 40 minutes. Methanol (10 m]) was added followed by solid sodium 2-ethylhexanoate (12 g) to bring the mixture to pH 50 6.9. The mixture was warmed to 25' and stirred at 25 for 3-1 hours. The crystalline material which had separated from the mixture was collected by filtration, washed with one bed volume of 1,2-dimethoxyethane followed by two bed volumes of acetone, and dried in vacuo at 35 to give sodium cefuroxime (10. 16 g).

Claims (8)

  1. CLAIMS 1. A process for the preparation of sodium cefuroxime of a solvate
    thereof which comprises subjecting a compound of formula :k 1 i GB 2 043 070A 5 H H 1 = S C. CO. NH _) 14,_ cl- of 0 N \OCH 3 0 N OCONHR 1 (1) COOR (wherein R' is a base-labile group) to alcoholysis in a substantially anhydrous solvent medium in 10 the presence of a basic catalyst soluble in the said medium, which basic catalyst comprises the sodium salt of an acid having a pK, value not les than 3.5, and subsequently recovering sodium cefuroxime or a solvate thereof.
  2. 2. A process as claimed in claim 1 wherein R' in the compound of formula 1 is a chlorinated lower alkanoyl group.
  3. 3. A process as claimed in claim 2 wherein R' in the compound of formula 1 is a trichloroacetyl group.
  4. 4. A process as claimed in any one of claims 1 to 3 wherein the basic catalyst comprises a sodium salt of a C2-10 alkanoic acid.
  5. 5. A process as claimed in claim 4 wherein the basic catalyst comprises sodium 2ethylhexanoate.
  6. 6. A process as claimed in any one of claims 1 to 5 wherein the alcoholysis is effected using methanol and/or ethane- 1, 2-diol.
  7. 7. A process as claimed in any one of claims 1 to 6 wherein. the solvent medium is tetrahydrofuran or a mixture thereof with dichloromethane or hexane.
  8. 8. Sodium cefuroxime tetrahydrofuran solvate.
    Printed for Her Majesty's Stationery Office by Burgess & Son (Abingdon) Ltd.-1 980. Published at The Patent Office, 25 Southampton Buildings, London, WC2A 1 AY, from which copies may be obtained.
    1
GB8005088A 1979-02-15 1980-02-14 Preparation of sodium cefuroxime Expired GB2043070B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7905456 1979-02-15

Publications (2)

Publication Number Publication Date
GB2043070A true GB2043070A (en) 1980-10-01
GB2043070B GB2043070B (en) 1983-03-23

Family

ID=10503234

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8005088A Expired GB2043070B (en) 1979-02-15 1980-02-14 Preparation of sodium cefuroxime

Country Status (18)

Country Link
US (1) US4277601A (en)
JP (1) JPS55111490A (en)
KR (1) KR830001905B1 (en)
AT (1) AT366051B (en)
AU (1) AU542084B2 (en)
CH (1) CH646706A5 (en)
DE (1) DE3005564A1 (en)
DK (1) DK159449C (en)
ES (1) ES488607A0 (en)
FI (1) FI75168C (en)
FR (1) FR2482104A1 (en)
GB (1) GB2043070B (en)
HU (1) HU182068B (en)
IT (1) IT1144037B (en)
NL (1) NL191844C (en)
SE (1) SE451724B (en)
YU (1) YU42325B (en)
ZA (1) ZA80844B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549836A1 (en) * 1983-07-29 1985-02-01 Glaxo Group Ltd PROCESS FOR PREPARING SODIUM SALT OF CEFUROXIME

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS588086A (en) * 1981-07-07 1983-01-18 Takeda Chem Ind Ltd Solvated cephalosporin and its preparation
AT411996B (en) * 2000-09-11 2004-08-26 Sandoz Ag METHOD FOR PRODUCING CEFUROXIME IN THE FORM OF ITS N-BUTYL LAMONIUM SALTS
WO2004050663A2 (en) * 2002-12-05 2004-06-17 Orchid Chemicals & Pharmaceuticals Ltd An improved process for the preparation of cefuroxime sodium
ITMI20050871A1 (en) 2005-05-13 2006-11-14 Acs Dobfar Spa CEFUROXIMA ACID CRYSTALLINE SOLVATE
CN102617604A (en) * 2012-02-24 2012-08-01 天津大学 Method utilizing coupling reaction crystallization to prepare cefuroxime sodium
CN104774211A (en) * 2015-04-27 2015-07-15 四川制药制剂有限公司 Preparation technique of cefuroxime sodium for injection
WO2017191620A1 (en) * 2016-05-06 2017-11-09 Sun Pharmaceutical Industries Limited A crystalline form of a salt of sacubitril and a process of its preparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3974153A (en) * 1971-05-14 1976-08-10 Glaxo Laboratories Limited 7-Hydrocarbonoxy imino-acetamido-3-carbamoyloxy methylceph-3-em-4 carboxylic acids
US3905963A (en) * 1972-01-25 1975-09-16 Lilly Co Eli Process for preparing primary 3-carbamoyloxymethyl cephalosporins
GB1575905A (en) * 1976-04-28 1980-10-01 Glaxo Lab Ltd Salt of cefuroxime

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549836A1 (en) * 1983-07-29 1985-02-01 Glaxo Group Ltd PROCESS FOR PREPARING SODIUM SALT OF CEFUROXIME
GB2145408A (en) * 1983-07-29 1985-03-27 Glaxo Group Ltd Improvements in or relating to preparing sodium cefuroxime
AU567359B2 (en) * 1983-07-29 1987-11-19 Glaxo Group Limited Preparation of sodium cefuroxime
US4775750A (en) * 1983-07-29 1988-10-04 Glaxo Group Limited Process for preparing sodium cefuroxime

Also Published As

Publication number Publication date
FI75168C (en) 1988-05-09
FR2482104B1 (en) 1983-11-18
HU182068B (en) 1983-12-28
FI75168B (en) 1988-01-29
SE451724B (en) 1987-10-26
AU542084B2 (en) 1985-02-07
DE3005564C2 (en) 1989-05-24
NL8000925A (en) 1980-08-19
FR2482104A1 (en) 1981-11-13
KR830001905B1 (en) 1983-09-19
AT366051B (en) 1982-03-10
DK159449C (en) 1991-03-04
ZA80844B (en) 1981-08-26
JPH0240676B2 (en) 1990-09-12
YU42325B (en) 1988-08-31
KR830001952A (en) 1983-05-21
CH646706A5 (en) 1984-12-14
AU5556180A (en) 1980-08-21
DE3005564A1 (en) 1980-09-11
DK63280A (en) 1980-08-16
IT1144037B (en) 1986-10-29
ATA81380A (en) 1981-07-15
NL191844B (en) 1996-05-01
YU39580A (en) 1983-04-30
US4277601A (en) 1981-07-07
NL191844C (en) 1996-09-03
SE8001177L (en) 1980-08-16
JPS55111490A (en) 1980-08-28
DK159449B (en) 1990-10-15
GB2043070B (en) 1983-03-23
IT8047899A0 (en) 1980-02-14
ES8101607A1 (en) 1980-12-16
ES488607A0 (en) 1980-12-16
FI800453A (en) 1980-08-16

Similar Documents

Publication Publication Date Title
US4775750A (en) Process for preparing sodium cefuroxime
US5026843A (en) Process for the preparation of ceftriaxone
JPH0313237B2 (en)
US4277601A (en) Preparation of sodium cefuroxime
EP0302145B1 (en) Method for preparing crystalline cefadroxil monohydrate
GB2264944A (en) 2-amino-2,4,4-trimethylpentane salt of clavulanic acid
DE2431484C2 (en) Process for the preparation of 7 beta-amino-7 alpha-methoxy-3-cephemesters
US4935508A (en) Process for cephem prodrug esters
US5409918A (en) Crystalline cephem acid addition salts and process for their preparation
SU841590A3 (en) Method of preparing derivatives of 7-/2-(2-amino-4-thiazolyl)-2-alkoxyminoacetamido/-3-3(1,2,4-thiadiazol-5-ylthiomethyl)ceph-3-em-4-carboxylic acid or their salts with alkaline metals in the form of sin-isomers
US3454557A (en) 6-(alpha-guanidino acylamino)-penicillanic acid compounds
US4132789A (en) 7-[2-(2-Imino-4-thiazolin-4-yl)-2-sulfoacetamido]cephalosporins and antibacterial compositions containing them
EP0023045B1 (en) Imidazolecarboxylic acid derivatives of penicillins and cephalosporins
US3678051A (en) Derivatives of 1,6-phenazinediol 5,10-dioxide
US3996236A (en) Methoxymethyl D-6-(2,2-dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)penicillanate
KR100423890B1 (en) New process for preparing cephalosporin derivative
SU543353A3 (en) The method of obtaining derivatives of 7-monochloroacetamido-3-deacetoxycephalosporanic acid
US3555017A (en) Derivative of 7-acylaminocephalosporanic acid
US3164604A (en) 6-aminopenicillanic acid
US4168375A (en) Process for the recovery of cephalosporin C and derivatives thereof
KR830001970B1 (en) Method for preparing cephalosporin derivative
US3188311A (en) Process for the preparation of 7-amino-cephalosporanic acids
JPH0780890B2 (en) Process for producing 6- [D (-)-α- (4-ethyl-2,3-dioxopiperazin-1-ylcarbonylamino) -α-phenylacetamido] -penicillanic acid
KR860001369B1 (en) Process for preparing penicillanic acid esters
KR860000345B1 (en) Process for preparing cephalosporin derivatives

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Effective date: 20000213